Literature DB >> 19465855

What is the role for surgery in patients with stage III non-small cell lung cancer?

Elke Vandenbroucke1, Frederic De Ryck, Veerle Surmont, Jan P van Meerbeeck.   

Abstract

PURPOSE OF REVIEW: Locally advanced non-small cell lung cancer (NSCLC) represents a therapeutic challenge. Although combined modality has become the standard treatment in stage III NSCLC, the role of surgery in it remains controversial. This review will address recent evidence on the potential role of surgery in either superior sulcus tumors, T4N0-1 tumors with central extension multifocal tumors with nodule(s) in the same lobe, or stage III disease with mediastinal lymph node involvement. RECENT
FINDINGS: Two recent phase 2 trials, exploring surgical resection preceded by induction chemoradiotherapy for tumors of the superior sulcus, have reported an impressive survival with acceptable mortality rate. They confirm the outcome observed in other prospective and retrospective series for T3-4N0-1. For subsets of T4 NSCLC with central extension or with satellite nodule(s) in the primary lobe, cumulative data suggest that these tumors behave differently than other stage IIIB tumors and might benefit from upfront surgery, possibly followed by postoperative chemotherapy and/or radiotherapy. Whenever clinical mediastinal lymph node invasion is present, surgery after induction treatment is not proven superior to radiotherapy, and is best restricted to clinical trials.
SUMMARY: Combined modality treatment is the standard of care for locally advanced NSCLC and the optimal role for surgery remains a challenging issue for the clinicians.

Entities:  

Mesh:

Year:  2009        PMID: 19465855     DOI: 10.1097/MCP.0b013e32832cbefc

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  2 in total

1.  The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.

Authors:  Joaquim Bosch-Barrera; Carlos García-Franco; Francisco Guillén-Grima; Marta Moreno-Jiménez; José María López-Picazo; Alfonso Gúrpide; José Luis Pérez-Gracia; Javier Aristu; Wenceslao Torre; Jesús García-Foncillas; Ignacio Gil-Bazo
Journal:  Clin Transl Oncol       Date:  2012-07-20       Impact factor: 3.405

2.  [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer].

Authors:  Yu Zhang; Hongling Lu; Gang Xu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-08-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.